Brivanib
- Generic Name
- Brivanib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19FN4O3
- CAS Number
- 649735-46-6
- Unique Ingredient Identifier
- DDU33B674I
- Background
Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 29
- Registration Number
- NCT00437437
- Locations
- ๐บ๐ธ
Dana-Farber Harvard Cancer Care, Boston, Massachusetts, United States
๐บ๐ธWayne State University, Detroit, Michigan, United States
๐บ๐ธDuke University Medical Center-Dept Of Medicine, Durham, North Carolina, United States
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT00437424
- Locations
- ๐ช๐ธ
Local Institution, Sevilla, Spain
๐บ๐ธUniversity Of Alabama At Birmingham, Birmingham, Alabama, United States
๐บ๐ธUsc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
- Conditions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2009-01-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT00435669
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT00390936
- Locations
- ๐ฏ๐ต
Local Institution, Sunto-Gun, Shizuoka, Japan
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT00207103
- Locations
- ๐บ๐ธ
Premiere Oncology, Santa Monica, California, United States
๐บ๐ธUniversity Of Wisconsin Comprehensive Center, Madison, Wisconsin, United States
๐ฌ๐งLocal Institution, Manchester, Greater Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.